P53-altered FBXW7 expression determines poor prognosis in gastric cancer cases

Cancer Research

Volumn 69, Issue 9, 2009, Pages 3788-3794

  Yokobori, Takehiko ^a,b   Mimori, Koshi ^a   Iwatsuki, Masaaki ^a   Ishii, Hideshi ^a   Onoyama, Ichiro ^c   Fukagawa, Takeo ^d   Kuwano, Hiroyuki ^b   Nakayama, Keiichi I ^c   Mori, Masaki ^e  

^a KYUSHU UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN P53;

AGED; ARTICLE; CONTROLLED STUDY; FBXW7 GENE; FEMALE; GENE CONTROL; GENE DISRUPTION; GENE EXPRESSION; GENE FUNCTION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MUTATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; TUMOR VOLUME;

CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; F-BOX PROTEINS; GENE EXPRESSION; GENES, P53; HUMANS; MUTATION; PROGNOSIS; RNA INTERFERENCE; RNA, MESSENGER; STOMACH NEOPLASMS; UBIQUITIN-PROTEIN LIGASES;

EID: 65949107856     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2846     Document Type: Article

References (32)

1. Nakayama KI, Nakayama K. Ubiquitin ligases:cellcycle control and cancer. Nat Rev Cancer 2006; 6: 369-81.
2. Welcker M, Clurman BE. FBW7 ubiquitin ligase:a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008; 8: 83-93.
3. Mao JH, Perez-Losada J, Wu D, et al. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 2004; 432: 775-9.
4. Akhoondi S, Sun D, von der Lehr N, et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007; 67: 9006-12.
5. Matsumoto A, Onoyama I, Nakayama KI. Expression of mouse Fbxw7 isoforms is regulated in a cell cycle- or p53-dependent manner. Biochem Biophys Res Commun 2006; 350: 114-9.
6. Onoyama I, Tsunematsu R, Matsumoto A, et al. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med 2007; 204: 2875-88.
7. Matsuoka S, Oike Y, Onoyama I, et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev 2008; 22: 986-91.
8. Kimura T, Gotoh M, Nakamura Y, Arakawa H. hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci 2003; 94: 431-6.
9. Nakayama KI, Nakayama K. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol 2005; 16: 323-33.
10. Yan T, Wunder JS, Gokgoz N, Seto KK, Bell RS, Andrulis IL. hCDC4 variation in osteosarcoma. Cancer Genet Cytogenet 2006; 169: 138-42.
11. Hagedorn M, Delugin M, Abraldes I, et al. FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients. Cell Div 2007; 2: 9.
12. Bredel M, Bredel C, Juric D, et al. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 2005; 65: 8679-89.
13. Lee JW, Soung YH, Kim HJ, et al. Mutational analysis of the hCDC4 gene in gastric carcinomas. Eur J Cancer 2006; 42: 2369-73.
14. Enders GH. Cyclins in breast cancer:too much of a good thing. Breast Cancer Res 2002; 4: 145-7.
15. Ogawa K, Utsunomiya T, Mimori K, et al. Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res 2005; 11: 2889-93.
16. Ieta K, Ojima E, Tanaka F, et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer 2007; 121: 33-8.
17. Ieta K, Tanaka F, Utsunomiya T, Kuwano H, Mori M. CEACAM6 gene expression in intrahepatic cholangiocarcinoma. Br J Cancer 2006; 95: 532-40.
18. Welcker M, Orian A, Grim JE, Eisenman RN, Clurman BE. A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr Biol 2004; 14: 1852-7.
19. Minella AC, Grim JE, Welcker M, Clurman BE. p53 and SCF (Fbw7) cooperatively restrain cyclin E-associated genome instability. Oncogene 2007; 26: 6948-53.
20. Malyukova A, Dohda T, von der Lehr N, et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 2007; 67: 5611-6.
21. Tan Y, Sangfelt O, Spruck C. The Fbxw7/hCdc4 tumor suppressor in human cancer. Cancer Lett 2008; 271: 1-12.
22. Sterian A, Kan T, Berki AT, et al. Mutational and LOH analyses of the chromosome 4q region in esophageal adenocarcinoma. Oncology 2006; 70: 168-72.
23. Sundqvist A, Bengoechea-Alonso MT, Ye X, et al. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF (Fbw7). Cell Metab 2005; 1: 379-91.
24. Takada H, Imoto I, Tsuda H, et al. Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization. Cancer Sci 2005; 96: 100-10.
25. Welcker M, Orian A, Jin J, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A 2004; 101: 9085-90.
26. Welcker M, Singer J, Loeb KR, et al. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell 2003; 12: 381-92.
27. Spencer CA, Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 1991; 56: 1-48.
28. Onoyama I. Cyclin E and c-Myc degradation by SCF (Fbxw7). Tanpakushitsu Kakusan Koso 2006; 51: 1382-5.
29. Ji P, Zhu L. Using kinetic studies to uncover new Rb functions in inhibiting cell cycle progression. Cell Cycle 2005; 4: 373-5.
30. Zindy F, Eischen CM, Randle DH, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998; 12: 2424-33.
31. Pelengaris S, Khan M. The many faces of c-MYC. Arch Biochem Biophys 2003; 416: 129-36.
32. Soucek L, Whitfield J, Martins CP, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455: 679-83.